Publication: Molecular biomarkers for quantitative and discrete COPD phenotypes
Issued Date
2009-03-01
Resource Type
ISSN
10441549
Other identifier(s)
2-s2.0-61549124380
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Respiratory Cell and Molecular Biology. Vol.40, No.3 (2009), 359-367
Suggested Citation
Soumyaroop Bhattacharya, Sorachai Srisuma, Dawn L. Demeo, Steven D. Shapiro, Raphael Bueno, Edwin K. Silverman, John J. Reilly, Thomas J. Mariani Molecular biomarkers for quantitative and discrete COPD phenotypes. American Journal of Respiratory Cell and Molecular Biology. Vol.40, No.3 (2009), 359-367. doi:10.1165/rcmb.2008-0114OC Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/27278
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Molecular biomarkers for quantitative and discrete COPD phenotypes
Abstract
Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disorder with complex pathological features and largely unknown etiology. The identification of biomarkers for this disease could aid the development of methods to facilitate earlier diagnosis, the classification of disease subtypes, and provide a means to define therapeutic response. To identify gene expression biomarkers, we completed expression profiling of RNA derived from the lung tissue of 56 subjects with varying degrees of airflow obstruction using the Affymetrix U133 Plus 2.0 array. We applied multiple, independent analytical methods to define biomarkers for either discrete or quantitative disease phenotypes. Analysis of differential expression between cases (n = 15) and controls (n = 18) identified a set of 65 discrete biomarkers. Correlation of gene expression with quantitative measures of airflow obstruction (FEV1%predicted or FEV1/FVC) identified a set of 220 biomarkers. Biomarker genes were enriched in functions related to DNA binding and regulation of transcription. We used this group of biomarkers to predict disease in an unrelated data set, generated from patients with severe emphysema, with 97% accuracy. Our data contribute to the understanding of gene expression changes occurring in the lung tissue of patients with obstructive lung disease and provide additional insight into potential mechanisms involved in the disease process. Furthermore, we present the first gene expression biomarker for COPD validated in an independent data set.